Key result
BM-573, a dual thromboxane receptor antagonist and synthase inhibitor, demonstrated antiplatelet and antithrombotic activities in vitro and protected pigs from myocardial infarction in vivo.
Answers are grounded in this paper and cite their sources.
BM-573 is a novel dual TXA2 synthase inhibitor and receptor antagonist with promising antiplatelet, antithrombotic, and cardiopulmonary protective effects in preclinical models.
BM-573 (N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea), a torsemide derivative, is a novel non-carboxylic dual TXA2 synthase inhibitor and receptor antagonist. The pharmacological profile of the drug is characterized by a higher affinity for the thromboxane receptor than that of SQ-29548, one of the most powerful antagonists described to date, by a complete prevention of human platelet aggregation induced by arachidonic acid at a lower dose than either torsemide or sulotroban, and by a significantly prolonged closure time measured by the platelet function analyser (PFA-100). Moreover, at the concentrations of 1 and 10 microM, BM-573 completely prevented production of TXB2 by human platelets activated by 0.6 mM of arachidonic acid. BM-573 prevents rat fundus contraction induced by U-46619 but not by prostacyclin or other prostaglandins. Despite possessing a chemical structure very similar to that of a diuretic torsemide, BM-573 has no diuretic activity. BM-573 does not prolong bleeding time and, unlike some of the other sulfonylureas, has no effect on blood glucose levels. In vivo, BM-573 appears to have antiplatelet and antithrombotic activities since it reduced thrombus weight and prolonged the time to abdominal aorta occlusion induced by ferric chloride. BM-573 also relaxed rat aorta and guinea pig trachea precontracted with U-46619. In pigs, BM-573 completely antagonized pulmonary hypertensive effects of U-46619 and reduced the early phase of pulmonary hypertension in models of endotoxic shock and pulmonary embolism. Finally, BM-573 protected pigs from myocardial infarction induced by coronary thrombosis. These results suggest that BM-573 should be viewed as a promising therapeutic agent in the treatment of pulmonary hypertension and syndromes associated with platelet activation.
No takes yet. Share an insight, caveat, or question.
Ghuysen et al. (2005) studied Pulmonary hypertension and syndromes associated with platelet activation. BM-573 vs. SQ-29548, torsemide, sulotroban was evaluated on Pharmacological profile including platelet aggregation, TXB2 production, and in vivo antithrombotic effects. BM-573, a dual thromboxane receptor antagonist and synthase inhibitor, demonstrated antiplatelet and antithrombotic activities in vitro and protected pigs from myocardial infarction in vivo.
Synapse has enriched 10 related papers. Consider them for comparative context: